These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 17441358)

  • 21. Serum tumor marker CYFRA 21-1 in the diagnostics of squamous cell lung cancer--comparison with CEA.
    Berzinec P; Zuffová H; Letkovicová M; Arpásová M
    Neoplasma; 1996; 43(3):159-61. PubMed ID: 8841502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
    Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
    J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Value of combined detection of tumor markers for the prediction of small cell and non-small cell lung cancer].
    Wu Y; Wu Y; Wang L; Qu L
    Wei Sheng Yan Jiu; 2000 Jul; 29(4):213-5. PubMed ID: 12520921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of serum SELDI proteomic patterns in diagnosis of lung cancer.
    Yang SY; Xiao XY; Zhang WG; Zhang LJ; Zhang W; Zhou B; Chen G; He DC
    BMC Cancer; 2005 Jul; 5():83. PubMed ID: 16029516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
    Ebert W; Hoppe M; Muley T; Drings P
    Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preliminary evaluation of the new tumor marker, CYFRA 21-1, in lung cancer patients.
    Koga H; Eguchi K; Shinkai T; Tamura T; Ohe Y; Oshita F; Saijo N; Kondo H; Oki K; Okura H
    Jpn J Clin Oncol; 1994 Oct; 24(5):263-8. PubMed ID: 7526016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
    Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
    Ebert W; Muley T; Drings P
    Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical evaluation of combination assay of tumor markers in primary lung cancer patients].
    Hatakeyama S; Nagai A; Kioi S; Arakawa M
    Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Aug; 28(8):1053-8. PubMed ID: 2173801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study of telomerase activity in pleural lavage fluid specimens in patients with non-small-cell lung cancer and its clinical significance.
    Li W; Ni Y; Tu Z; Wu S; Wu Z; Zheng S
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):460-4. PubMed ID: 19502078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Serum lipid-bound sialic acid as a marker in lung cancer patients].
    Iwahashi N
    Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Dec; 28(12):1599-607. PubMed ID: 2077205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer.
    Gaspar MJ; Diez M; Rodriguez A; Ratia T; Martin Duce A; Galvan M; Granell J; Coca C
    Anticancer Res; 2003; 23(4):3427-32. PubMed ID: 12926084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Philipp M; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Clin Exp Med; 2003 Feb; 2(4):185-91. PubMed ID: 12624710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Blood tumor markers in patients with lung cancer].
    Bianco A; Marcatili P; D'Auria D; Sorrentino P; Zofra S
    Ann Ital Med Int; 1996; 11(2):114-8. PubMed ID: 8974436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions.
    Gaspar MJ; De Miguel J; García Díaz JD; Díez M
    Anticancer Res; 2008; 28(5B):2947-52. PubMed ID: 19031938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of tumor markers including carcinoembryonic antigen, APC, and cyclin D2 in fine-needle aspiration fluid of breast.
    Lee A; Kim Y; Han K; Kang CS; Jeon HM; Shim SI
    Arch Pathol Lab Med; 2004 Nov; 128(11):1251-6. PubMed ID: 15508191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Usefulness of CYFRA21-1 as a tumor marker of non-small-cell lung cancer].
    Tan Y; Zhang P; Zheng C
    Zhonghua Zhong Liu Za Zhi; 1999 Jul; 21(4):287-9. PubMed ID: 11776818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
    Zhao XW; Jiang B; Han CZ; Jing JX
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.